Revenio Acquires Visionix, Boosting Eye Care Tech

Revenio Group, a prominent Finnish player in ophthalmic diagnostics, has finalized its acquisition of Visionix International group, a move that significantly reshapes the global eye care technology sector. This strategic integration creates a formidable, independent provider of comprehensive diagnostic and imaging solutions, aiming to capture a larger share of the expanding eye health market.

The transaction, valued at an enterprise worth of EUR 290 million on a debt-free, cash-free basis, saw Revenio pay EUR 250 million in cash and issue approximately EUR 55.7 million in new shares. This acquisition of Visionix's parent, LT International SAS, officially closed on May 28, 2026, following its initial signing on April 13, 2026. The combined entity is set to leverage complementary strengths, with Revenio's established iCare tonometry platform now augmented by Visionix's advanced OCT (Optical Coherence Tomography) imaging, including its Optovue system, and other diagnostic tools.

This consolidation is poised to unlock substantial market opportunities. Industry analysts project the combined entity's total addressable market in eye care diagnostics and imaging could expand by as much as 2.5 times. The integration is expected to accelerate market penetration into the high-growth OCT segment, a critical area for early disease detection and patient management in ophthalmology and optometry.

Pro forma financial figures for 2025 illustrate the scale of the new enterprise. Combined sales are projected to exceed EUR 250 million, with adjusted EBITDA reaching EUR 48 million. The expanded organization will employ over 800 professionals across its global operations, offering a unified suite of products encompassing diagnostic devices, sophisticated imaging systems, and practice management software. This broad portfolio addresses the entire patient eye care pathway, from initial screening to advanced diagnostics.

Looking ahead, Revenio has set ambitious synergy targets. The company anticipates achieving approximately EUR 20 million in EBITDA synergies by the end of 2029, driven by operational efficiencies and expanded cross-selling initiatives. The strategic vision includes achieving annual revenue growth three times the market rate, with EBITDA margins climbing to 25% between 2028 and 2029, and potentially nearing 30% beyond 2030. This aggressive growth trajectory underscores the confidence in the combined entity's market position and operational capabilities.

The eye care diagnostics market, valued at over USD 10 billion globally and projected to grow at a CAGR of 6-8%, presents a fertile ground for such strategic consolidations. The increasing prevalence of age-related eye conditions and the growing demand for early detection technologies are key drivers. By combining iCare's established presence in tonometry with Visionix's cutting-edge OCT technology, Revenio is positioning itself as a leader capable of offering end-to-end solutions to optical retailers, optometrists, and ophthalmologists worldwide.